NO3083625T3 - - Google Patents
Info
- Publication number
- NO3083625T3 NO3083625T3 NO14815843A NO14815843A NO3083625T3 NO 3083625 T3 NO3083625 T3 NO 3083625T3 NO 14815843 A NO14815843 A NO 14815843A NO 14815843 A NO14815843 A NO 14815843A NO 3083625 T3 NO3083625 T3 NO 3083625T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322602.2A GB201322602D0 (en) | 2013-12-19 | 2013-12-19 | Pharmaceutical compounds |
| PCT/GB2014/053793 WO2015092431A1 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3083625T3 true NO3083625T3 (https=) | 2018-03-31 |
Family
ID=50071157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO14815843A NO3083625T3 (https=) | 2013-12-19 | 2014-12-19 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9850247B2 (https=) |
| EP (1) | EP3083625B1 (https=) |
| JP (1) | JP6437559B2 (https=) |
| KR (1) | KR102405462B1 (https=) |
| CN (1) | CN105829315B (https=) |
| AU (1) | AU2014369457B2 (https=) |
| BR (1) | BR112016014151B1 (https=) |
| CA (1) | CA2933755C (https=) |
| CY (1) | CY1120035T1 (https=) |
| DK (1) | DK3083625T3 (https=) |
| ES (1) | ES2650013T3 (https=) |
| GB (1) | GB201322602D0 (https=) |
| HR (1) | HRP20180080T1 (https=) |
| HU (1) | HUE037908T2 (https=) |
| IL (1) | IL245672B (https=) |
| LT (1) | LT3083625T (https=) |
| MX (1) | MX371108B (https=) |
| NO (1) | NO3083625T3 (https=) |
| NZ (1) | NZ720178A (https=) |
| PL (1) | PL3083625T3 (https=) |
| PT (1) | PT3083625T (https=) |
| RS (1) | RS56731B1 (https=) |
| RU (1) | RU2691105C1 (https=) |
| SG (1) | SG11201603814TA (https=) |
| SI (1) | SI3083625T1 (https=) |
| SM (1) | SMT201800020T1 (https=) |
| WO (1) | WO2015092431A1 (https=) |
| ZA (1) | ZA201603337B (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10364247B2 (en) * | 2015-04-21 | 2019-07-30 | Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine | Preparation and use of novel protein kinase inhibitors |
| JP6692423B2 (ja) * | 2015-11-01 | 2020-05-13 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法 |
| US10703759B2 (en) | 2016-11-16 | 2020-07-07 | Impact Therapeutics, Inc | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones |
| WO2018124001A1 (ja) | 2016-12-27 | 2018-07-05 | 国立研究開発法人理化学研究所 | Ｂｍｐシグナル阻害化合物 |
| WO2018133829A1 (zh) * | 2017-01-23 | 2018-07-26 | 南京明德新药研发股份有限公司 | 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 |
| GB201703881D0 (en) * | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
| US20200108074A1 (en) | 2017-03-31 | 2020-04-09 | Seattle Genetics, Inc. | Combinations of chk1- and wee1- inhibitors |
| US11345710B2 (en) | 2017-07-10 | 2022-05-31 | Impact Therapeutics (Shanghai), Inc | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| US10807994B2 (en) | 2017-10-09 | 2020-10-20 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2019074979A1 (en) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| DK3712150T3 (da) | 2017-11-01 | 2024-07-29 | Wuxi Biocity Biopharmaceutics Co Ltd | Makrocyklisk forbindelse, der tjener som wee1-hæmmer, og anvendelser deraf |
| EP3758706A4 (en) | 2018-02-28 | 2021-11-24 | The Regents Of The University Of Colorado | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF |
| AU2019348120A1 (en) * | 2018-09-27 | 2021-05-06 | Betta Pharmaceuticals Co., Ltd | FGFR4 inhibitor and use thereof |
| JP7481336B2 (ja) | 2018-10-26 | 2024-05-10 | ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド | Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用 |
| EP3902805A4 (en) | 2018-12-28 | 2023-03-01 | SPV Therapeutics Inc. | CYCLINE-DEPENDENT KINASE INHIBITORS |
| EP3943496A4 (en) | 2019-03-22 | 2022-05-18 | Shouyao Holdings (Beijing) Co., Ltd. | Wee1 inhibitor and preparation and use thereof |
| CN113939296A (zh) | 2019-04-09 | 2022-01-14 | 诺维逊生物股份有限公司 | 杂环化合物及其用途 |
| US20220162229A1 (en) * | 2019-04-09 | 2022-05-26 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| US20220168313A1 (en) * | 2019-04-09 | 2022-06-02 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| CN113784968B (zh) | 2019-04-30 | 2024-03-15 | 无锡智康弘义生物科技有限公司 | Wee1抑制剂化合物的晶型及其应用 |
| CN112142763B (zh) * | 2019-06-28 | 2024-01-26 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| US12522607B2 (en) | 2020-06-17 | 2026-01-13 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors |
| WO2022072336A1 (en) * | 2020-10-01 | 2022-04-07 | University Of Washington | Drug-like molecules and methods for the therapeutic targeting of microrna-21 |
| US12551584B1 (en) | 2020-12-07 | 2026-02-17 | Actinium Pharmaceuticals, Inc. | Lewis Y radioimmunotherapy for the treatment of cancer |
| JP2024502231A (ja) * | 2020-12-18 | 2024-01-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｎａｖ１．８電位依存性ナトリウムチャネルを阻害するためおよびＮａｖ１．８介在疾患を治療するために有用な化学化合物 |
| JP2023554430A (ja) * | 2020-12-18 | 2023-12-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｎａｖ１．８阻害剤としての含窒素２，３－ジヒドロキナゾリノン化合物 |
| AU2022265032A1 (en) | 2021-04-30 | 2023-11-16 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof |
| BR112023025403A2 (pt) | 2021-06-25 | 2024-02-20 | Korea Res Inst Chemical Tech | Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo |
| CN116462687B (zh) | 2022-01-18 | 2025-01-07 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| CN116836184B (zh) * | 2022-03-25 | 2025-07-25 | 药雅科技(上海)有限公司 | Wee1激酶抑制剂的制备及其应用 |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| CN117402162A (zh) | 2022-07-13 | 2024-01-16 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| TW202519226A (zh) | 2023-11-08 | 2025-05-16 | 美商艾克塞里克斯公司 | 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| EP1727819A1 (en) | 2004-03-15 | 2006-12-06 | F.Hoffmann-La Roche Ag | Novel dichloro-phenyl-pyrido¬2,3-d|pyrimidine derivatives, their manufacture and use as pharmaceutical agents |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| JP5411847B2 (ja) | 2007-04-25 | 2014-02-12 | Ｍｓｄ株式会社 | Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 |
| ES2608940T3 (es) | 2007-06-15 | 2017-04-17 | Msd K.K. | Derivado de bicicloanilina |
| EP2213673B1 (en) | 2007-10-23 | 2013-06-05 | Msd K.K. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| EP2376493B1 (en) | 2008-12-12 | 2016-10-05 | Msd K.K. | Dihydropyrimidopyrimidine derivative |
| CA2745959A1 (en) * | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivatives |
| PE20140421A1 (es) * | 2010-12-06 | 2014-04-26 | Glaxo Group Ltd | COMPUESTOS DERIVADOS DE PIRIMIDINONA COMO INHIBIDORES DE Lp-PLA2 |
| AR084515A1 (es) * | 2010-12-22 | 2013-05-22 | Merz Pharma Gmbh & Co Kgaa | Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras |
| TWI532742B (zh) * | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| US8716297B2 (en) | 2011-07-15 | 2014-05-06 | Abbvie Inc. | Chemical entities to be used for Wee1 inhibition for the treatment of cancer |
| WO2013013031A1 (en) * | 2011-07-19 | 2013-01-24 | Abbvie Inc. | Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase |
| US9181239B2 (en) | 2011-10-20 | 2015-11-10 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| CN104271576A (zh) * | 2012-02-23 | 2015-01-07 | 艾伯维公司 | 激酶的吡啶并嘧啶酮抑制剂 |
| CN102816164A (zh) * | 2012-08-31 | 2012-12-12 | 北京理工大学 | 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法 |
-
2013
- 2013-12-19 GB GBGB1322602.2A patent/GB201322602D0/en not_active Ceased
-
2014
- 2014-12-19 SG SG11201603814TA patent/SG11201603814TA/en unknown
- 2014-12-19 PL PL14815843T patent/PL3083625T3/pl unknown
- 2014-12-19 EP EP14815843.9A patent/EP3083625B1/en active Active
- 2014-12-19 KR KR1020167019551A patent/KR102405462B1/ko active Active
- 2014-12-19 BR BR112016014151-2A patent/BR112016014151B1/pt active IP Right Grant
- 2014-12-19 NZ NZ720178A patent/NZ720178A/en unknown
- 2014-12-19 PT PT148158439T patent/PT3083625T/pt unknown
- 2014-12-19 AU AU2014369457A patent/AU2014369457B2/en active Active
- 2014-12-19 HU HUE14815843A patent/HUE037908T2/hu unknown
- 2014-12-19 WO PCT/GB2014/053793 patent/WO2015092431A1/en not_active Ceased
- 2014-12-19 CN CN201480069437.9A patent/CN105829315B/zh active Active
- 2014-12-19 MX MX2016007801A patent/MX371108B/es active IP Right Grant
- 2014-12-19 ES ES14815843.9T patent/ES2650013T3/es active Active
- 2014-12-19 LT LTEP14815843.9T patent/LT3083625T/lt unknown
- 2014-12-19 US US15/105,869 patent/US9850247B2/en active Active
- 2014-12-19 SI SI201430580T patent/SI3083625T1/en unknown
- 2014-12-19 JP JP2016541294A patent/JP6437559B2/ja active Active
- 2014-12-19 DK DK14815843.9T patent/DK3083625T3/en active
- 2014-12-19 CA CA2933755A patent/CA2933755C/en active Active
- 2014-12-19 RS RS20171338A patent/RS56731B1/sr unknown
- 2014-12-19 SM SM20180020T patent/SMT201800020T1/it unknown
- 2014-12-19 HR HRP20180080TT patent/HRP20180080T1/hr unknown
- 2014-12-19 RU RU2016123363A patent/RU2691105C1/ru active
- 2014-12-19 NO NO14815843A patent/NO3083625T3/no unknown
-
2016
- 2016-05-17 IL IL245672A patent/IL245672B/en unknown
- 2016-05-17 ZA ZA2016/03337A patent/ZA201603337B/en unknown
-
2018
- 2018-01-15 CY CY20181100041T patent/CY1120035T1/el unknown